drugset / Trial / NCT01809769

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis

NCT01809769 ↗

Phase 1/2 Completed 18 enrolled Shanghai AbelZeta Ltd. RenJi Hospital · collab
RandomizedSingle-groupDouble-blindTreatment

Summary

Two injections in total and 3 ml autologous adipose-tissue-derived stem cells(haMSCs) for each injection; time-points for intervention: 1) initial injection; 2) 3 weeks following initial injection.

Timeline

Start
2013-03
Primary completion
2015-03
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Adipose tissue derived mesenchymal stem cells Cell therapy 1e+07 cells Other
Subject Adipose tissue derived mesenchymal stem cells Cell therapy 2e+07 cells Other
Subject Adipose tissue derived mesenchymal stem cells Cell therapy 5e+07 cells Other

Indications